Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation
- PMID: 7585980
- DOI: 10.1006/cimm.1995.0006
Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation
Abstract
Several studies have demonstrated that addition of soluble anti-CD6 mAbs to 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated naive T cells can induce cell proliferation. We showed in the present study that cell proliferation in TPA-treated T cell cultures can be enhanced several fold when the anti-CD6 mAbs are either immobilized or crosslinked with rabbit anti-mouse immunoglobulins (RAM Ig). Using a src family protein tyrosine kinase (PTK) inhibitor, herbimycin A, the cell proliferation induced by the anti-CD6 mAb, IOR-T1, in TPA-treated T cells were effectively abolished. Analysis of the cellular proteins in these cells after crosslinking the CD6 receptor with IOR-T1 (followed by RAM Ig) in the presence of TPA resulted in an increased level of tyrosine phosphorylation. Pretreatment of native T cells with herbimycin A (0.5 and 1 microgram/ml) for 18 hr completely inhibited the tyrosine phosphorylation on cellular substrates in T cell cultures stimulated with IOR-T1/RAM Ig and TPA. Similar concentrations of herbimycin A also inhibited the increase in IL-2 mRNA expression and cell proliferation in T cell cultures after IOR-T1/RAM Ig and TPA treatment. Furthermore, the increase in cytosolic free Ca2+ concentration in naive T cells after crosslinking of the CD6 receptor with IOR-T1/RAM Ig was also inhibited by herbimycin A. Taken together, our results suggest that CD6-mediated T cell proliferation is IL-2 dependent, and involves tyrosine kinase activity which is strictly dependent on protein kinase C activation.
Similar articles
-
CD28-induced T cell activation. Evidence for a protein-tyrosine kinase signal transduction pathway.J Immunol. 1992 Jul 1;149(1):24-9. J Immunol. 1992. PMID: 1318900
-
Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism.J Immunol. 1997 Aug 1;159(3):1115-24. J Immunol. 1997. PMID: 9233604
-
Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B cells from apoptosis.Eur J Immunol. 1993 Oct;23(10):2578-84. doi: 10.1002/eji.1830231030. Eur J Immunol. 1993. PMID: 7691610
-
CD6 as a therapeutic target in autoimmune diseases: successes and challenges.BioDrugs. 2013 Jun;27(3):191-202. doi: 10.1007/s40259-013-0027-4. BioDrugs. 2013. PMID: 23568178 Review.
-
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.Curr Drug Targets. 2016;17(6):666-77. doi: 10.2174/1389450117666160201114308. Curr Drug Targets. 2016. PMID: 26844560 Review.
Cited by
-
Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.Front Immunol. 2018 Oct 9;9:2333. doi: 10.3389/fimmu.2018.02333. eCollection 2018. Front Immunol. 2018. PMID: 30356797 Free PMC article.
-
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.Arthritis. 2010;2010:130646. doi: 10.1155/2010/130646. Epub 2011 Feb 10. Arthritis. 2010. PMID: 22076177 Free PMC article.
-
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.Clin Exp Immunol. 2010 Oct;162(1):116-30. doi: 10.1111/j.1365-2249.2010.04235.x. Epub 2010 Aug 19. Clin Exp Immunol. 2010. PMID: 20726988 Free PMC article.
-
The OT-II model reveals dual in vitro and in vivo immunomodulatory properties of CD6 in T cell activation.Front Immunol. 2025 Jun 26;16:1571590. doi: 10.3389/fimmu.2025.1571590. eCollection 2025. Front Immunol. 2025. PMID: 40642095 Free PMC article.
-
The role of CD6 in autoimmune diseases.Cell Mol Immunol. 2018 Nov;15(11):1001-1002. doi: 10.1038/s41423-018-0015-1. Epub 2018 Mar 23. Cell Mol Immunol. 2018. PMID: 29572546 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous